How were Dimension Therapeutics' earnings last quarter?

Dimension Therapeutics, Inc. (NASDAQ:DMTX) released its earnings results on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.20. The biotechnology company had revenue of $4.48 million for the quarter.

What other stocks do shareholders of Dimension Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dimension Therapeutics investors own include Corbus Pharmaceuticals (CRBP) , Cross Timbers Royalty Trust (CRT) , Innovative Industrial Properties (IIPR) , Palatin Technologies (PTN) , Aldeyra Therapeutics (ALDX) , Allena Pharmaceuticals (ALNA) , Ampliphi Biosciences (APHB) , Aquinox Pharmaceuticals (AQXP) , Ardelyx (ARDX) and Atara Biotherapeutics (ATRA) .

NASDAQ:DMTX

Dimension Therapeutics (DMTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free DMTX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $5.95
▼
$5.95
50-Day Range: N/A
52-Week Range: $1.05
▼
$6.10

Volume: N/A
Average Volume: 150,214 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Dimension Therapeutics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Dimension Therapeutics Stock (NASDAQ:DMTX)

Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

DMTX Stock News Headlines

March 18, 2024 | yahoo.com

Play Mahjong Dimensions Online for Free | Yahoo! Games

December 11, 2023 | news.bbc.co.uk

Pitch dimensions

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

July 26, 2023 | bbc.co.uk

Russia warns of 'new dimension' in Ukraine war

May 25, 2023 | finance.yahoo.com

KAYS - Kaya Holdings, Inc.

March 11, 2023 | seekingalpha.com

Nano Dimension offers to acquire Stratasys for $18 a share (update)

January 12, 2023 | msn.com

Anime Dimensions Codes (January 2023)

January 5, 2023 | msn.com

Startup Trying to Test Whether People on DMT Experience a Shared Alien Universe

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 24, 2022 | finance.yahoo.com

METAVERSE ARTISTS PSYONICS HAVE MUST-SEE PERFORMANCE IN VIRTUAL LIVE ENTERTAINMENT PLATFORM VRJAM'S "5TH DIMENSION"

September 22, 2022 | finance.yahoo.com

Unlimited Dimension DODOOR NFTs Explained

June 8, 2022 | marketwatch.com

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2022 Size, Share, Applications, Advance Technology and Top Companies to 2028

See More Headlines

Receive DMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dimension Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2017
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:DMTX
CUSIP: N/A
CIK: 1592288
Web: dimensiontx.com
Phone: +1-617-4010011
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Georges Gemayel Ph.D. (Age 56)
Chairman of the Board
Annalisa M. Jenkins (Age 52)
President, Chief Executive Officer, Director
Mary T. Thistle (Age 57)
Principal Financial and Accounting Officer, Chief Operating Officer
Samuel C. Wadsworth Ph.D. (Age 68)
Chief Scientific Officer
Eric Crombez M.D. (Age 44)
Chief Medical Officer
John Hohneker (Age 57)
Director
Alan B. Colowick M.D. (Age 54)
Independent Director
Michael Dybbs Ph.D. (Age 42)
Independent Director
George V. Migausky (Age 62)
Independent Director
Arlene M. Morris (Age 65)
Independent Director

DMTX Stock Analysis - Frequently Asked Questions

How were Dimension Therapeutics' earnings last quarter?: Dimension Therapeutics, Inc. (NASDAQ:DMTX) released its earnings results on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.20. The biotechnology company had revenue of $4.48 million for the quarter.
What other stocks do shareholders of Dimension Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dimension Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Cross Timbers Royalty Trust (CRT), Innovative Industrial Properties (IIPR), Palatin Technologies (PTN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Aquinox Pharmaceuticals (AQXP), Ardelyx (ARDX) and Atara Biotherapeutics (ATRA).

This page (NASDAQ:DMTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dimension Therapeutics (DMTX) Stock Price, News & Analysis

About Dimension Therapeutics Stock (NASDAQ:DMTX)

DMTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

DMTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info